2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Carcinoma, Non-Small Cell Lung in 41 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with sesamin caused cell cycle arrest at G1 phase and inhibited cyclin D1 and CDK2 expression." | 1.56 | Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway. ( Chen, Y; Huang, H; Li, H; Liu, B; Lu, C; Qi, W; Yang, Z; Zhang, L; Zhang, W, 2020) |
| " The present study investigated the effect of hydrogen‑rich saline alone and in combination with the PI3K inhibitor, LY294002, on the proliferation, oxidative stress and apoptosis of NSCLC A549 cells." | 1.48 | Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer. ( Cheng, S; Guo, S; Jiang, Y; Liao, Y; Liu, G; Luo, C; Zhang, L, 2018) |
| " Besides, xenograft experiment showed that combination with autophagy inhibitor potentiated the anti-tumor efficacy of rhArg in vivo." | 1.46 | A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. ( Cao, Z; Fan, J; Fu, X; Ju, D; Luan, J; Shen, W; Xu, Z; Yang, P; Zhang, X, 2017) |
| "Curcumin has been reported to cause inhibition on proliferation and induction of apoptosis in many human cancer cell lines, including non-small cell lung cancer cells (NSCLC)." | 1.38 | Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. ( Chuu, CP; Kuo, LK; Lin, HP, 2012) |
| " The objective of this study was to evaluate the effect of various SPI, both alone and in combination with cisplatin, on three different non-small cell lung cancer (NSCLC) cell lines." | 1.35 | Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. ( El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009) |
| "In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell." | 1.33 | Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. ( Huang, B; Porter, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (41.46) | 29.6817 |
| 2010's | 21 (51.22) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 2 |
| Li, H | 3 |
| Zhang, W | 2 |
| Qi, W | 1 |
| Lu, C | 1 |
| Huang, H | 1 |
| Yang, Z | 1 |
| Liu, B | 1 |
| Zhang, L | 3 |
| Sun, T | 1 |
| Zhang, J | 4 |
| Deng, B | 1 |
| Fan, X | 1 |
| Long, T | 1 |
| Jin, H | 1 |
| Tao, S | 1 |
| Kang, P | 1 |
| Tan, Q | 1 |
| Chen, JC | 1 |
| Ko, JC | 1 |
| Taso, YC | 1 |
| Cheng, HH | 1 |
| Chen, TY | 1 |
| Yen, TC | 1 |
| Lin, YW | 1 |
| Shen, W | 1 |
| Zhang, X | 2 |
| Fu, X | 1 |
| Fan, J | 1 |
| Luan, J | 1 |
| Cao, Z | 1 |
| Yang, P | 1 |
| Xu, Z | 2 |
| Ju, D | 1 |
| Hu, J | 1 |
| Chen, Q | 1 |
| Lin, J | 1 |
| Wang, S | 1 |
| Liu, R | 1 |
| Miao, K | 1 |
| Shou, T | 1 |
| Jiang, Y | 1 |
| Liu, G | 1 |
| Cheng, S | 1 |
| Luo, C | 1 |
| Liao, Y | 1 |
| Guo, S | 1 |
| Baruah, TJ | 1 |
| Kma, L | 1 |
| Liu, L | 1 |
| Zhou, XY | 1 |
| Zhang, JQ | 1 |
| Wang, GG | 1 |
| He, J | 1 |
| Chen, YY | 1 |
| Huang, C | 1 |
| Li, L | 2 |
| Li, SQ | 1 |
| Liu, D | 1 |
| Fan, C | 1 |
| Luan, L | 1 |
| Wang, E | 1 |
| Ito, S | 1 |
| Igishi, T | 2 |
| Takata, M | 1 |
| Ueda, Y | 1 |
| Matsumoto, S | 1 |
| Kodani, M | 2 |
| Takeda, K | 2 |
| Izumi, H | 1 |
| Sakamoto, T | 1 |
| Yamaguchi, K | 1 |
| Makino, H | 1 |
| Touge, H | 1 |
| Chikumi, H | 1 |
| Shimizu, E | 2 |
| Ning, J | 1 |
| Liu, W | 1 |
| Lang, Y | 1 |
| Xu, S | 1 |
| Jin, Q | 1 |
| Lee, HJ | 1 |
| Min, HY | 1 |
| Smith, JK | 1 |
| Hwang, SJ | 1 |
| Whang, YM | 1 |
| Kim, WY | 1 |
| Kim, YH | 1 |
| Lee, HY | 2 |
| Porcelli, L | 1 |
| Giovannetti, E | 2 |
| Assaraf, YG | 1 |
| Jansen, G | 1 |
| Scheffer, GL | 1 |
| Kathman, I | 1 |
| Azzariti, A | 1 |
| Paradiso, A | 1 |
| Peters, GJ | 2 |
| Zhu, L | 1 |
| Wang, Z | 1 |
| Lin, Y | 1 |
| Chen, Z | 2 |
| Liu, H | 1 |
| Wang, N | 1 |
| Song, X | 1 |
| Ni, Y | 2 |
| Wang, L | 1 |
| Pang, Z | 1 |
| Liu, Q | 1 |
| Du, J | 1 |
| Dogan Turacli, I | 1 |
| Ozkan, AC | 1 |
| Ekmekci, A | 1 |
| Yang, J | 1 |
| Qin, G | 1 |
| Luo, M | 1 |
| Chen, J | 1 |
| Zhang, Q | 1 |
| Pan, L | 1 |
| Qin, S | 1 |
| Kikuchi, J | 1 |
| Kinoshita, I | 1 |
| Shimizu, Y | 1 |
| Oizumi, S | 1 |
| Nishimura, M | 1 |
| Birrer, MJ | 1 |
| Dosaka-Akita, H | 1 |
| Kilic, A | 1 |
| Schuchert, MJ | 1 |
| Luketich, JD | 1 |
| Landreneau, RJ | 1 |
| El-Hefnawy, T | 1 |
| Deng, QF | 1 |
| Su, B | 2 |
| Zhao, YM | 1 |
| Zhou, CC | 1 |
| Cortes-Sempere, M | 1 |
| Chattopadhyay, S | 1 |
| Rovira, A | 1 |
| Rodriguez-Fanjul, V | 1 |
| Belda-Iniesta, C | 1 |
| Tapia, M | 1 |
| Cejas, P | 1 |
| Machado-Pinilla, R | 1 |
| Manguan-García, C | 1 |
| Sánchez-Pérez, I | 1 |
| Nistal, M | 1 |
| Moratilla, C | 1 |
| de Castro-Carpeño, J | 1 |
| Gonzalez-Barón, M | 1 |
| Albanell, J | 1 |
| Perona, R | 1 |
| Kelly-Spratt, KS | 1 |
| Philipp-Staheli, J | 1 |
| Gurley, KE | 1 |
| Hoon-Kim, K | 1 |
| Knoblaugh, S | 1 |
| Kemp, CJ | 1 |
| Petersen, SL | 1 |
| Peyton, M | 1 |
| Minna, JD | 1 |
| Wang, X | 4 |
| Zhang, C | 1 |
| Elkahloun, AG | 1 |
| Liao, H | 1 |
| Delaney, S | 1 |
| Saber, B | 1 |
| Morrow, B | 1 |
| Prendergast, GC | 1 |
| Hollander, MC | 1 |
| Gills, JJ | 1 |
| Dennis, PA | 2 |
| Lin, HP | 1 |
| Kuo, LK | 1 |
| Chuu, CP | 1 |
| Schmid-Bindert, G | 1 |
| Wang, D | 1 |
| Zhao, Y | 1 |
| Yang, X | 1 |
| Zhou, C | 1 |
| Zhu, X | 1 |
| Long, L | 1 |
| Hui, L | 1 |
| Chen, H | 1 |
| Shen, H | 1 |
| Xu, W | 1 |
| Shultz, JC | 1 |
| Vu, N | 1 |
| Shultz, MD | 1 |
| Mba, MU | 1 |
| Shapiro, BA | 1 |
| Chalfant, CE | 1 |
| Han, R | 1 |
| Zhong, D | 1 |
| Zhao, J | 1 |
| Sun, L | 1 |
| Wang, J | 1 |
| Kijima, T | 1 |
| Maulik, G | 1 |
| Ma, PC | 1 |
| Tibaldi, EV | 1 |
| Turner, RE | 1 |
| Rollins, B | 1 |
| Sattler, M | 1 |
| Johnson, BE | 1 |
| Salgia, R | 1 |
| Nguyen, DM | 1 |
| Chen, GA | 1 |
| Reddy, R | 1 |
| Tsai, W | 1 |
| Schrump, WD | 1 |
| Cole, G | 1 |
| Schrump, DS | 1 |
| Sun, SY | 1 |
| Rosenberg, LM | 1 |
| Zhou, Z | 1 |
| Yue, P | 1 |
| Fu, H | 1 |
| Khuri, FR | 1 |
| Oh, SH | 1 |
| Suh, YA | 1 |
| Baek, JH | 1 |
| Papadimitrakopoulou, V | 1 |
| Huang, S | 1 |
| Hong, WK | 1 |
| Huang, B | 1 |
| Porter, G | 1 |
| Denlinger, CE | 1 |
| Rundall, BK | 1 |
| Jones, DR | 1 |
| Hemström, TH | 1 |
| Sandström, M | 1 |
| Zhivotovsky, B | 1 |
| Morita, M | 1 |
| Suyama, H | 1 |
| Shigeoka, Y | 1 |
| Hashimoto, K | 1 |
| Sumikawa, T | 1 |
| Lemos, C | 1 |
| Tekle, C | 1 |
| Smid, K | 1 |
| Nannizzi, S | 1 |
| Rodriguez, JA | 1 |
| Ricciardi, S | 1 |
| Danesi, R | 1 |
| Giaccone, G | 1 |
| Sos, ML | 1 |
| Zander, T | 1 |
| Thomas, RK | 1 |
| Staratschek-Jox, A | 1 |
| Claasen, J | 1 |
| Wolf, J | 1 |
| Park, JK | 1 |
| Jung, HY | 1 |
| Park, SH | 1 |
| Kang, SY | 1 |
| Yi, MR | 1 |
| Um, HD | 1 |
| Hong, SH | 1 |
| Brognard, J | 1 |
| Clark, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study[NCT05132985] | Phase 2 | 45 participants (Anticipated) | Interventional | 2022-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
41 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
Topics: Animals; Apoptosis; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolifera | 2020 |
FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Ce | 2020 |
Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzoquinones; Bevacizumab; Carcinoma, Non-Small-Cel | 2021 |
A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor.
Topics: Apoptosis; Arginase; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Chrom | 2017 |
Knockdown of CPEB4 expression suppresses cell migration and invasion via Akt pathway in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Chromones; Gene Knockdown Technique | 2018 |
Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Chromones; Heme Oxygenase-1; Humans; Hydrogen; Lung Neop | 2018 |
Vicenin-2 acts as a radiosensitizer of the non-small cell lung cancer by lowering Akt expression.
Topics: Apigenin; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survi | 2019 |
LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Topics: Adult; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolifer | 2018 |
DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Fema | 2014 |
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anthracyclines; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2014 |
Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Enzyme Activation; Enzyme Inhibitors; E | 2013 |
Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Chromones; Humans; Insulin- | 2014 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporter | 2014 |
Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway.
Topics: Adaptor Proteins, Signal Transducing; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2015 |
PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.
Topics: Aminopyridines; Benzamides; Blotting, Western; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line | 2015 |
The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Topics: Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromon | 2015 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor | 2015 |
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin A; Cyclin-De | 2008 |
Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In | 2009 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2008 |
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; | 2009 |
Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Chromones; Cyclin-Dependent Kinase Inhibitor | 2009 |
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence | 2010 |
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Cluster Analysis | 2011 |
Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Biological Availability; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell | 2012 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell | 2011 |
miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
Topics: Carcinoma, Non-Small-Cell Lung; Chromones; Down-Regulation; Doxorubicin; Humans; Lung Neoplasms; Mic | 2012 |
The Proto-oncogene PKCι regulates the alternative splicing of Bcl-x pre-mRNA.
Topics: Alternative Splicing; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Ce | 2012 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug | 2012 |
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Division; Cell Movement; Cell Size; | 2002 |
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromon | 2004 |
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processe | 2005 |
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Topics: Adenoviridae; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Casp | 2005 |
Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Breast Neoplasms; Butadienes; Carcinoma, Non- | 2005 |
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Chromones; Enzyme Inhibitors; Histone Deacetylas | 2005 |
Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell S | 2006 |
Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Chromone | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extra | 2008 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screeni | 2008 |
Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Death; Ce | 2008 |
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromones; Drug Screening Assays, Antitumo | 2001 |